A United Kingdom-based economic evaluation of ranibizumab for patients with retinal vein occlusion (RVO)

Author： Taylor Matthew   Serbetci Elçin   Ferreira Alberto   Gairy Kerry   Lewis Lily   Blouin Julie   Mitchell Paul  

Publisher： Informa Healthcare

ISSN： 1369-6998

Source： Journal of Medical Economics, Vol.17, Iss.6, 2014-06, pp. : 423-434

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Characteristics of retinal vein occlusion (RVO) patients with macular edema who lasted remission more than 6 months after single injection of intravitreal bevacizumab

By  

ACTA OPHTHALMOLOGICA, Vol. 94, Iss. S256, 2016-10 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment outcome of switching from ranibizumab to aflibercept in patients with central retinal vein occlusion

By  

ACTA OPHTHALMOLOGICA, Vol. 94, Iss. S256, 2016-10 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Incidence of retinal vein occlusions (RVO) in patients treated with oral anticoagulants or antiplatelet drugs for cardioembolic or atherothrombotic prevention

By  

ACTA OPHTHALMOLOGICA, Vol. 94, Iss. S256, 2016-10 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Head‐to‐head comparison of ranibizumab PRN versus single‐dose dexamethasone for branch retinal vein occlusion (COMRADE‐B)

By  

ACTA OPHTHALMOLOGICA, Vol. 96, Iss. 1, 2018-02 ,pp. : e10-e18

John Wiley & Sons Inc

Access to resources Recommend Favorite

Economic evaluation of sevelamer for the treatment of hyperphosphatemia in chronic kidney disease patients not on dialysis in the United Kingdom

By Thompson Melissa  

Journal of Medical Economics, Vol. 16, Iss. 6, 2013-06 ,pp. : 744-755

Informa Healthcare

Access to resources Recommend Favorite